Fanghui Ren1, Xin Zhang1, Haiwei Liang1, Dianzhong Luo1, Minhua Rong2, Yiwu Dang1, Gang Chen1. 1. Department of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China. 2. Department of Research, Affiliated Cancer Hospital, Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China.
Abstract
PURPOSE: The aim of the present meta-analysis and systematic review was to explore the association between the expression of miR-34a and prognosis in solid tumor. METHODS: PubMed, Google Scholar, Web of Science and NCBI databases were used to search studies to evaluate the effect of miR-34a expression on clinical outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS) and event-free survival (EFS) in solid tumor. The pooled random effect models were performed to calculate pooled hazard ratio (HR), 95% confidence interval (CI) to assess the association. RESULTS: Twenty-three eligible studies with 4030 patients were included in this meta-analysis. It was confirmed that increased expression of miR-34a was in relevant with better DFS/RFS/PFS/EFS, which was identified with both univariate and multivariate models (univariate model: HR = 0.62, 95% CI: 0.42-0.92, P = 0.019; multivariate model: HR = 0.55, 95% CI: 0.34-0.88, P = 0.013). Furthermore, in the analysis of relationship between miR-34a and DFS/RFS/PFS/EFS, the results remained similar when excluding the studies contributed to the heterogeneity (univariate analysis: HR = 0.57, 95% CI: 0.46-0.70, P < 0.001; multivariate analysis: HR = 0.57, 95% CI: 0.43-0.75, P < 0.001). With univariate analysis, it was also demonstrated that miR-34a overexpression might be positively associated with a favorable OS in solid tumor (HR = 0.73, 95% CI: 0.54-1.00, P = 0.005) with considering an obvious heterogeneity. CONCLUSION: Our current study supports the notion that miR-34a may be a potential biomarker to predict OS and RFS/PFS/DFS/EFS in solid tumor.
PURPOSE: The aim of the present meta-analysis and systematic review was to explore the association between the expression of miR-34a and prognosis in solid tumor. METHODS: PubMed, Google Scholar, Web of Science and NCBI databases were used to search studies to evaluate the effect of miR-34a expression on clinical outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS) and event-free survival (EFS) in solid tumor. The pooled random effect models were performed to calculate pooled hazard ratio (HR), 95% confidence interval (CI) to assess the association. RESULTS: Twenty-three eligible studies with 4030 patients were included in this meta-analysis. It was confirmed that increased expression of miR-34a was in relevant with better DFS/RFS/PFS/EFS, which was identified with both univariate and multivariate models (univariate model: HR = 0.62, 95% CI: 0.42-0.92, P = 0.019; multivariate model: HR = 0.55, 95% CI: 0.34-0.88, P = 0.013). Furthermore, in the analysis of relationship between miR-34a and DFS/RFS/PFS/EFS, the results remained similar when excluding the studies contributed to the heterogeneity (univariate analysis: HR = 0.57, 95% CI: 0.46-0.70, P < 0.001; multivariate analysis: HR = 0.57, 95% CI: 0.43-0.75, P < 0.001). With univariate analysis, it was also demonstrated that miR-34a overexpression might be positively associated with a favorable OS in solid tumor (HR = 0.73, 95% CI: 0.54-1.00, P = 0.005) with considering an obvious heterogeneity. CONCLUSION: Our current study supports the notion that miR-34a may be a potential biomarker to predict OS and RFS/PFS/DFS/EFS in solid tumor.
Authors: Sameer Abdallah Dhayat; Max Michael Traeger; Jan Rehkaemper; Anda Jana Stroese; Konrad Steinestel; Eva Wardelmann; Iyad Kabar; Norbert Senninger Journal: Cancers (Basel) Date: 2018-09-13 Impact factor: 6.639